DC vaccine therapy combined concurrently with oral capecitabine in metastatic colorectal cancer patients

Hepato-Gastroenterology

Volumn 60, Issue 122, 2013, Pages 23-27

  Liu, Yandi ^a   Zhang, Wenhua ^a   Zhang, Baofeng ^a   Yin, Xiaodong ^a   Pang, Yan ^a  

^a TIANJIN UNION MEDICAL CENTER   (China)

Author keywords

Capecitabine; Colorectal cancer; DC vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CD56 ANTIGEN; DENDRITIC CELL VACCINE; DEXAMETHASONE; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE STRENGTH; NAUSEA AND VOMITING; PRIORITY JOURNAL; SKIN ALLERGY; SURVIVAL TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 84877705152     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/12522     Document Type: Article

References (30)

1. Chen LT, Whang-Peng J: Current status of clinical studies for colorectal cancer in Taiwan. Clin Colorectal Cancer 2004; 4:196-203.
2. Bretthauer M: Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol 2010; 24:417-425.
3. Atkin WS, Edwards R, Kralj-Hans I, et al.: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomized controlled trial. Lancet 2010; 375:1624-1633.
4. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
5. Moore S: Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs 2007; 30:112-122.
6. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y: Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 2006; 57:693-702.
7. Van Cutsem E, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106. (Pubitemid 33049527)
8. Chu E, Schulman KL, McKenna EF Jr, Cartwright T: Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. Clin Colorectal Cancer 2010; 9:229-237.
9. Rao B, Han M, Wang L, et al.: Clinical outcomes of active specific immunotherapy in metastatic colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med 2011; 9:17.
10. Burgdorf SK: Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull 2010; 57:B4171.
11. Barth RJ Jr, Fisher DA, Wallace PK, et al.: A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res 2010; 16:5548-5556.
12. Kim JY, Ju MK, Kim MS, et al.: Clinical characteristics and treatment outcomes of colorectal cancer in renal transplant recipients in Korea. Yonsei Med J 2011; 52:454-462.
13. Toh HC, Wang WW, Chia WK, et al.: Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin Cancer Res 2009; 15:7726-7736.
14. Cui G, Shi Y, Cui J, Tang F, Florholmen J: Immune microenvironmental shift along human colorectal adenoma-carcinoma sequence: is it relevant to tumor development, biomarkers and biotherapeutic targets? Scand J Gastroenterol 2012; 47:367-377.
15. Barth RJ Jr, Fisher DA, Wallace PK, et al.: A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res 2010; 16:5548-5556.
16. Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM: Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011; 2011:437348.
17. Mosolits S, Nilsson B, Mellstedt H: Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines 2005; 4:329-350. (Pubitemid 40978696)
18. Nicol AJ, Tazbirkova A, Nieda M: Comparison of clinical and immunological effects of intravenous and intradermal administration of α- galactosylceramide (KRN7000)-pulsed dendritic cells. Clin Cancer Res 2011; 17:5140-5151.
19. El Haj M, Ya'acov AB, Lalazar G, Han Y: Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis. World J Gastroenterol 2007; 13:5799-5804. (Pubitemid 350148496)
20. Hoos A, Eggermont AM, Janetzki S, et al.: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388-1397.
21. Jähnisch H, Füssel S, Kiessling A, et al.: Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol 2010; 2010:517493.
22. Nowak AK, Robinson BW, Lake RA: Gemcitabine exerts a selective effect on the tumoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002; 62:2353-2358. (Pubitemid 34411717)
23. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73.
24. Harrop R, Drury N, Shingler W, et al.: Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007; 13:4487-94. (Pubitemid 47219718)
25. Zitvogel L, Apetoh L, Ghiringhelli F, et al.: The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001. (Pubitemid 351872317)
26. Dudley ME, Wunderlich JR, Yang JC, et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-2357. (Pubitemid 46218728)
27. Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005; 65:8059-8064. (Pubitemid 41330564)
28. Ma Y, Zhang Z, Tang L, et al.: Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012; 14:483-493.
29. Kim BR, Yang EK, Kim DY, et al.: Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma. Clin Exp Immunol 2012; 167:73-83.
30. Lesterhuis WJ, de Vries IJ, Aarntzen EA, et al.: A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer 2010; 103:1415-1421.